CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
Portfolio Pulse from
CervoMed announced positive results from the extension phase of its Phase 2b clinical study of neflamapimod in patients with dementia with Lewy bodies. The new batch of neflamapimod capsules showed increased plasma drug concentrations and demonstrated improvement.
March 10, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CervoMed's Phase 2b study of neflamapimod in dementia with Lewy bodies showed positive results, with improved drug concentrations and patient outcomes.
The positive results from the Phase 2b study of neflamapimod are likely to boost investor confidence in CervoMed, as the drug shows promise in treating dementia with Lewy bodies. This could lead to increased interest and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100